[1] Ubhi K, Masliah E. Alzheimer’s disease: recent advances and future perspectives [J]. J Alzheimers Dis, 2013, 33:S185-194.
[2] Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers [J]. Biochem Pharmacol, 2014, 88(4):640-651.
[3] Chan K Y, Wang W, Wu J J, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis [J]. Lancet, 2013, 381(9882):2016-2023.
[4] Dubois B, Feldman H H, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria [J]. Lancet Neurol, 2014, 13 (6):614-629.
[5] Terry R D, Gonatas N K, Weiss M. Ultrastructural studies in alzheimer’s presenile dementia [J]. Am J Pathol, 1964, 44:269-297.
[6] Glenner G G, Wong C W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein [J]. Biochem Biophys Res Commun, 1984, 120(3):885-890.
[7] Hardy J A, Higgins G A. Alzheimer’s disease: the amyloid cascade hypothesis [J]. Science, 1992, 256(5054):184-185.
[8] Kung H F. The β-Amyloid hypothesis in Alzheimer’s disease seeing is believing [J]. ACS Med Chem Lett, 2012, 3(4):265-267.
[9] McLean C A, Cherny R A, Fraser F W, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease [J]. Ann Neurol, 1999, 46(6):860-866.
[10] Klein W L, Krafft G A, Finch C E. Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum?[J].Trends Neurosci, 2001, 24(4):219-224.
[11] Morris E,Chalkidou A,Hammers A, et al. Diagnostic accuracy of (¹⁸)F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis [J]. Eur J Nucl Med Mol Imaging, 2016, 43(2):374-385.
[12] Agdeppa E D, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease [J]. J Neurosci, 2001, 21(24): 189.
[13] Shoghi-Jadid K, Small G W, Agdeppa E D, et al. Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease [J]. Am J Geriatr Psychiatry, 2002, 10(1): 24-35.
[14] Mathis C A, Bacskai B J, Kajdasz S T, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain [J]. Bioorg Med Chem Lett, 2002, 12(3):295-298.
[15] Klunk W E, Wang Y, Huang G F, et al. The binding of 2-(4’-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component [J]. J Neurosci, 2003, 23(6):2086-2092.
[16] Klunk W E, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B [J]. Ann Neurol, 2004, 55(3):306-319.
[17] Ng S, Villemagne V L, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease [J]. J Nucl Med, 2007, 48(4):547-552.
[18] 胡 晓, 李 林, 张 兰. 高特异性分子探针在阿尔茨海默病早期诊断及药物疗效评价中的研究进展 [J]. 国际药学研究杂志, 2016, 43(1):20-25.
[19] Villemagne V L, Pike K E, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease [J]. Ann Neurol, 2011, 69(1):181-192.
[20] Nordberg A. Amyloid imaging in Alzheimer’s disease [J]. Curr Opin Neurol, 2007, 20 (4): 398-402.
[21] Pike K E, Savage G, Villemagne V L, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease [J]. Brain, 2007, 130(11):2837-2844.
[22] Villemagne V L, Pike K E, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease [J]. Neuropsychologia, 2008, 46(6):1688-1697.
[23] Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study [J]. Neurology, 2009, 73(10):754-760.
[24] Rowe C C, Ellis K A, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging [J]. Neurobiol Aging, 2010, 31(8):1275-1283.
[25] Ikonomovic M D,Buckley C J,Heurling K, et al. Post-mortem histopatho-logy underlying β-amyloid PET imaging following flutemetamol F 18 injection [J]. Acta Neuropathol Commun, 2016, 4(1):130.
[26] Miki T,Shimada H,Kim J S, et al. Brain uptake and safety of Flutemeta-mol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subje-cts with amnestic mild cognitive impairment and healthy volunteers [J]. Ann N-ucl Med, 2017, 31(3):260-272.
[27] Wong D F, Rosenberg P B, Zhou Y, et al. In vivo imaging of amyloid de-position in Alzheimer disease using the radiolig and ¹⁸F-AV-45 (florbetapir[c-orrected] F 18) [J]. J Nucl Med, 2010, 51(6): 913-920.
[28] Wolk D A, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer’s disease:comparison of florbetapir and Pittsburgh compound-B positron emission tomography [J].J Neurol Neurosurg Psychiatry, 2012, 83(9): 923-926.
[29] Kingwell K. Alzheimer disease: Florbetapir-a useful tool to image amyloid load and predict cognitive decline in Alzheimer disease [J].Nat Rev Neurol, 2012, 8(9): 471.
[30] Camus V, Payoux P, Barre L, et al. Using PET with ¹⁸F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment [J]. Eur J Nucl Med Mol Imaging, 2012, 39(4):621-631.
[31] Hauser S L, Josephson S A, Johnston S C. Florbetapir: knowing one’s future [J]. Ann Neurol, 2012, 71(6): A6.